Omics and AI advance biomarker discovery for liver disease

New technologies allow the noninvasive detection and staging of asymptomatic alcohol-associated liver disease; further refinement of this approach could transform clinical management and improve patient outcomes.

Automated summary

The new technologies enable noninvasive detection and staging of asymptomatic alcohol-associated liver disease, potentially improving patient outcomes through better clinical management.